Ocular Sale Purchase Of Stock from 2010 to 2024

OCUL Stock  USD 9.09  0.26  2.94%   
Ocular Therapeutix Sale Purchase Of Stock yearly trend continues to be quite stable with very little volatility. The value of Sale Purchase Of Stock is projected to decrease to about 656 K. From the period between 2010 and 2024, Ocular Therapeutix, Sale Purchase Of Stock regression line of its data series had standard deviation of  385,775 and standard deviation of  385,775. View All Fundamentals
 
Sale Purchase Of Stock  
First Reported
2014-06-30
Previous Quarter
851 K
Current Value
492 K
Quarterly Volatility
17.6 M
 
Yuan Drop
 
Covid
Check Ocular Therapeutix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ocular Therapeutix's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 M, Interest Expense of 11.9 M or Selling General Administrative of 19 M, as well as many indicators such as Price To Sales Ratio of 5.79, Dividend Yield of 0.0 or PTB Ratio of 4.1. Ocular financial statements analysis is a perfect complement when working with Ocular Therapeutix Valuation or Volatility modules.
  
Check out the analysis of Ocular Therapeutix Correlation against competitors.
For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.

Latest Ocular Therapeutix's Sale Purchase Of Stock Growth Pattern

Below is the plot of the Sale Purchase Of Stock of Ocular Therapeutix over the last few years. It is Ocular Therapeutix's Sale Purchase Of Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ocular Therapeutix's overall financial position and show how it may be relating to other accounts over time.
Sale Purchase Of Stock10 Years Trend
Slightly volatile
   Sale Purchase Of Stock   
       Timeline  

Ocular Sale Purchase Of Stock Regression Statistics

Arithmetic Mean458,403
Geometric Mean276,467
Coefficient Of Variation84.16
Mean Deviation337,683
Median297,000
Standard Deviation385,775
Sample Variance148.8B
Range1M
R-Value0.77
Mean Square Error65.5B
R-Squared0.59
Significance0.0008
Slope66,344
Total Sum of Squares2.1T

Ocular Sale Purchase Of Stock History

2024656 K
2023851 K
2022940 K
2021985 K
2020747 K
2019451 K
2018297 K

About Ocular Therapeutix Financial Statements

Ocular Therapeutix investors utilize fundamental indicators, such as Sale Purchase Of Stock, to predict how Ocular Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Sale Purchase Of Stock851 K656 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Ocular Therapeutix is a strong investment it is important to analyze Ocular Therapeutix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ocular Therapeutix's future performance. For an informed investment choice regarding Ocular Stock, refer to the following important reports:
Check out the analysis of Ocular Therapeutix Correlation against competitors.
For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.29)
Revenue Per Share
0.529
Quarterly Revenue Growth
0.083
Return On Assets
(0.22)
Return On Equity
(0.73)
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.